iMDsoft and ErgoGroup announce framework agreement in Norway
The scope of the project is estimated to be as much as E29 million. The framework agreement follows the three existing iMDsoft installations in hospitals in the region,
Swedish Orphan Biovitrum (Sobi) has received a complete response letter from the US Food and Drug Administration (FDA) regarding its biologics licence application for nanoencapsulated sirolimus plus pegadricase (NASP), an investigational therapy intended for adults with uncontrolled gout.
The collaboration will combine ZyGEM’s advanced enzymatic nucleic acid extraction technology and Advalytix’s expertise in single-cell molecular tests for life science research and diagnostic applications, said ZyGEM. Advalytix
The Horizons-AMI trial was a prospective, single-blind, randomized, multi-center study conducted in 11 countries. Patients undergoing angioplasty were randomly assigned to receive either Angiomax (bivalirudin) with provisional use